Funding
Funding not disclosed
Founders
Product
Problem
Age-related macular degeneration (AMD) is a leading cause of vision loss, and current treatment modalities for advanced stages often involve invasive procedures or systemic therapies with potential side effects. There is a need for localized, targeted treatments that can effectively manage disease progression and preserve visual acuity.
Solution
Brachytix is developing an epimacular brachytherapy system designed for the localized treatment of AMD. This therapeutic approach utilizes targeted radiation delivery directly to the affected area of the macula. The system aims to provide a minimally invasive option to inhibit neovascularization and reduce lesion growth, thereby preserving or improving patient vision. By focusing on precise dose delivery, Brachytix seeks to offer a differentiated treatment option for patients with wet AMD.
Target Audience
The primary target audience includes ophthalmologists specializing in retinal diseases and patients diagnosed with wet age-related macular degeneration.
Features
- Epimacular brachytherapy delivery system for localized radiation treatment
- Targeted application to the macula for AMD therapy
- Designed to inhibit choroidal neovascularization (CNV)
- Potential for improved visual acuity and reduced lesion activity
- Minimally invasive therapeutic approach